\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"
Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP July 8, 2024 Alzheimer\u2019s disease (AD) affects a significant portion of older individuals, with its prevalence expected to rise in the coming years. Therefore, urgent strategies for prevention and pharmacologic treatments are crucial. The state-of-the-art of drug development for AD plays a pivotal role in combating this disease, providing critical insights annually. The 2024 Alzheimer\u2019s disease drug development report, recently published, offers a comprehensive overview of ongoing clinical trials and new drug developments targeting various pathways.Excitingly, over 70% of drugs in the pipeline now focus on novel pathways such as neurotransmitters and neuroinflammation. This marks a significant shift from a decade ago, when amyloid beta and tau dominated the landscape, now comprising only about a quarter of current drug development efforts.The report paints a new and promising picture summarized below. Following nearly two decades of intensive research without new therapies, recent progress includes the approval of disease-modifying therapies and symptomatic treatments for neuropsychiatric symptoms of AD: \u2022Two anti-amyloid monoclonal antibodies\u2014aducanumab and lecanemab\u2014approved last year, along with donanemab recently reviewed and approved by the FDA. \u2022Brexpiprazole, approved for treating agitation in AD-associated dementia. These successes are pivotal in AD therapy, showing that we can now slow disease progression and manage some clinical symptoms effectively. While a cure for AD remains elusive, optimism is warranted for several reasons: 1.Advances in understanding the disease over the past five years have significantly enhanced our ability to target specific and novel therapeutic avenues. 2.The current drug pipeline is robust, focusing on previously unexplored pathways with potential disease-modifying effects. 3.Improved diagnostic accuracy through biomarkers and brain imaging allows for more precise clinical trials, providing unprecedented insights into efficacy. In conclusion, while challenges persist, the landscape of AD treatment is evolving positively, offering hope for improved outcomes in the near future. Check out the recent blog: “The Mediterranean Diet: Past, Present, and Future ~ Domenico Pratico, MD, FCPP”Domenico Pratic\u00f2, MD, is the Scott Richards North Star Charitable Foundation Chair for Alzheimer\u2019s Research, Professor and Director of the Alzheimer\u2019s Center at Temple, and Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University You can find out more information on Dr. Domenico Pratico’s research papers here. Connect with Dr. Domenico Pratico on LinkedIn, Facebook, Twitter & Instagram Follow Dr Domenico Pratico‘s lab website here: Pratico Lab<\/p>\n","protected":false},"author":1,"featured_media":2871,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"","ocean_second_sidebar":"","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"","ocean_custom_header_template":"","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"","ocean_menu_typo_font_family":"","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"on","ocean_gallery_id":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","entry","has-media"],"yoast_head":"\n
Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab\" \/>\n<meta property=\"og:description\" content=\"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP July 8, 2024 Alzheimer\u2019s disease (AD) affects a significant portion of older individuals, with its prevalence expected to rise in the coming years. Therefore, urgent strategies for prevention and pharmacologic treatments are crucial. The state-of-the-art of drug development for AD plays a pivotal role in combating this disease, providing critical insights annually. The 2024 Alzheimer\u2019s disease drug development report, recently published, offers a comprehensive overview of ongoing clinical trials and new drug developments targeting various pathways.Excitingly, over 70% of drugs in the pipeline now focus on novel pathways such as neurotransmitters and neuroinflammation. This marks a significant shift from a decade ago, when amyloid beta and tau dominated the landscape, now comprising only about a quarter of current drug development efforts.The report paints a new and promising picture summarized below. Following nearly two decades of intensive research without new therapies, recent progress includes the approval of disease-modifying therapies and symptomatic treatments for neuropsychiatric symptoms of AD: \u2022Two anti-amyloid monoclonal antibodies\u2014aducanumab and lecanemab\u2014approved last year, along with donanemab recently reviewed and approved by the FDA. \u2022Brexpiprazole, approved for treating agitation in AD-associated dementia. These successes are pivotal in AD therapy, showing that we can now slow disease progression and manage some clinical symptoms effectively. While a cure for AD remains elusive, optimism is warranted for several reasons: 1.Advances in understanding the disease over the past five years have significantly enhanced our ability to target specific and novel therapeutic avenues. 2.The current drug pipeline is robust, focusing on previously unexplored pathways with potential disease-modifying effects. 3.Improved diagnostic accuracy through biomarkers and brain imaging allows for more precise clinical trials, providing unprecedented insights into efficacy. In conclusion, while challenges persist, the landscape of AD treatment is evolving positively, offering hope for improved outcomes in the near future. Check out the recent blog: “The Mediterranean Diet: Past, Present, and Future ~ Domenico Pratico, MD, FCPP”Domenico Pratic\u00f2, MD, is the Scott Richards North Star Charitable Foundation Chair for Alzheimer\u2019s Research, Professor and Director of the Alzheimer\u2019s Center at Temple, and Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University You can find out more information on Dr. Domenico Pratico’s research papers here. Connect with Dr. Domenico Pratico on LinkedIn, Facebook, Twitter & Instagram Follow Dr Domenico Pratico‘s lab website here: Pratico Lab\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\" \/>\n<meta property=\"og:site_name\" content=\"Pratico Lab\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/Domenico-Pratico\/pfbid02JhsGw29fbYaMRVRwXLeG2WMzVGJFNoLuQtpgewCCP9U1XHgHwWvYiQyLqXDJgjd8l\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-08T15:36:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-08T15:41:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2240\" \/>\n\t<meta property=\"og:image:height\" content=\"1260\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DomenicPratico1\" \/>\n<meta name=\"twitter:site\" content=\"@DomenicPratico1\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/thepraticolab.com\/#\/schema\/person\/e82b3365d082813f155670a67aa9e909\"},\"headline\":\"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP\",\"datePublished\":\"2024-07-08T15:36:03+00:00\",\"dateModified\":\"2024-07-08T15:41:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/thepraticolab.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\",\"url\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\",\"name\":\"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab\",\"isPartOf\":{\"@id\":\"https:\/\/thepraticolab.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png\",\"datePublished\":\"2024-07-08T15:36:03+00:00\",\"dateModified\":\"2024-07-08T15:41:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage\",\"url\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png\",\"contentUrl\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png\",\"width\":2240,\"height\":1260,\"caption\":\"Alzheimer\u2019s disease drug development an update (1)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thepraticolab.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thepraticolab.com\/#website\",\"url\":\"https:\/\/thepraticolab.com\/\",\"name\":\"Pratico Lab\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/thepraticolab.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thepraticolab.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/thepraticolab.com\/#organization\",\"name\":\"Pratico Lab\",\"url\":\"https:\/\/thepraticolab.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepraticolab.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2023\/12\/cropped-Pratico-Lab-Logo.webp\",\"contentUrl\":\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2023\/12\/cropped-Pratico-Lab-Logo.webp\",\"width\":134,\"height\":84,\"caption\":\"Pratico Lab\"},\"image\":{\"@id\":\"https:\/\/thepraticolab.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/people\/Domenico-Pratico\/pfbid02JhsGw29fbYaMRVRwXLeG2WMzVGJFNoLuQtpgewCCP9U1XHgHwWvYiQyLqXDJgjd8l\/\",\"https:\/\/x.com\/DomenicPratico1\",\"https:\/\/www.linkedin.com\/in\/domenico-pratico-a57817262\/?original_referer=httpswww.pratico-lab.com\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/thepraticolab.com\/#\/schema\/person\/e82b3365d082813f155670a67aa9e909\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepraticolab.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ca8ef8f4c2ed934c1d85f121fd2b164b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ca8ef8f4c2ed934c1d85f121fd2b164b?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/thepraticolab.com\"],\"url\":\"https:\/\/thepraticolab.com\/post\/author\/pratico\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/","og_locale":"en_US","og_type":"article","og_title":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab","og_description":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP July 8, 2024 Alzheimer\u2019s disease (AD) affects a significant portion of older individuals, with its prevalence expected to rise in the coming years. Therefore, urgent strategies for prevention and pharmacologic treatments are crucial. The state-of-the-art of drug development for AD plays a pivotal role in combating this disease, providing critical insights annually. The 2024 Alzheimer\u2019s disease drug development report, recently published, offers a comprehensive overview of ongoing clinical trials and new drug developments targeting various pathways.Excitingly, over 70% of drugs in the pipeline now focus on novel pathways such as neurotransmitters and neuroinflammation. This marks a significant shift from a decade ago, when amyloid beta and tau dominated the landscape, now comprising only about a quarter of current drug development efforts.The report paints a new and promising picture summarized below. Following nearly two decades of intensive research without new therapies, recent progress includes the approval of disease-modifying therapies and symptomatic treatments for neuropsychiatric symptoms of AD: \u2022Two anti-amyloid monoclonal antibodies\u2014aducanumab and lecanemab\u2014approved last year, along with donanemab recently reviewed and approved by the FDA. \u2022Brexpiprazole, approved for treating agitation in AD-associated dementia. These successes are pivotal in AD therapy, showing that we can now slow disease progression and manage some clinical symptoms effectively. While a cure for AD remains elusive, optimism is warranted for several reasons: 1.Advances in understanding the disease over the past five years have significantly enhanced our ability to target specific and novel therapeutic avenues. 2.The current drug pipeline is robust, focusing on previously unexplored pathways with potential disease-modifying effects. 3.Improved diagnostic accuracy through biomarkers and brain imaging allows for more precise clinical trials, providing unprecedented insights into efficacy. In conclusion, while challenges persist, the landscape of AD treatment is evolving positively, offering hope for improved outcomes in the near future. Check out the recent blog: “The Mediterranean Diet: Past, Present, and Future ~ Domenico Pratico, MD, FCPP”Domenico Pratic\u00f2, MD, is the Scott Richards North Star Charitable Foundation Chair for Alzheimer\u2019s Research, Professor and Director of the Alzheimer\u2019s Center at Temple, and Professor of Pharmacology at the Lewis Katz School of Medicine at Temple University You can find out more information on Dr. Domenico Pratico’s research papers here. Connect with Dr. Domenico Pratico on LinkedIn, Facebook, Twitter & Instagram Follow Dr Domenico Pratico‘s lab website here: Pratico Lab","og_url":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/","og_site_name":"Pratico Lab","article_publisher":"https:\/\/www.facebook.com\/people\/Domenico-Pratico\/pfbid02JhsGw29fbYaMRVRwXLeG2WMzVGJFNoLuQtpgewCCP9U1XHgHwWvYiQyLqXDJgjd8l\/","article_published_time":"2024-07-08T15:36:03+00:00","article_modified_time":"2024-07-08T15:41:55+00:00","og_image":[{"width":2240,"height":1260,"url":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@DomenicPratico1","twitter_site":"@DomenicPratico1","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#article","isPartOf":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/"},"author":{"name":"admin","@id":"https:\/\/thepraticolab.com\/#\/schema\/person\/e82b3365d082813f155670a67aa9e909"},"headline":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP","datePublished":"2024-07-08T15:36:03+00:00","dateModified":"2024-07-08T15:41:55+00:00","mainEntityOfPage":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/thepraticolab.com\/#organization"},"image":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage"},"thumbnailUrl":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/","url":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/","name":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP - Pratico Lab","isPartOf":{"@id":"https:\/\/thepraticolab.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage"},"image":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage"},"thumbnailUrl":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png","datePublished":"2024-07-08T15:36:03+00:00","dateModified":"2024-07-08T15:41:55+00:00","breadcrumb":{"@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#primaryimage","url":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png","contentUrl":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1.png","width":2240,"height":1260,"caption":"Alzheimer\u2019s disease drug development an update (1)"},{"@type":"BreadcrumbList","@id":"https:\/\/thepraticolab.com\/post\/alzheimers-disease-drug-development-an-update-domenico-pratico-md-fcpp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepraticolab.com\/"},{"@type":"ListItem","position":2,"name":"Alzheimer\u2019s disease drug development: an update ~ Domenico Pratico, MD, FCPP"}]},{"@type":"WebSite","@id":"https:\/\/thepraticolab.com\/#website","url":"https:\/\/thepraticolab.com\/","name":"Pratico Lab","description":"","publisher":{"@id":"https:\/\/thepraticolab.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepraticolab.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepraticolab.com\/#organization","name":"Pratico Lab","url":"https:\/\/thepraticolab.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepraticolab.com\/#\/schema\/logo\/image\/","url":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2023\/12\/cropped-Pratico-Lab-Logo.webp","contentUrl":"https:\/\/thepraticolab.com\/wp-content\/uploads\/2023\/12\/cropped-Pratico-Lab-Logo.webp","width":134,"height":84,"caption":"Pratico Lab"},"image":{"@id":"https:\/\/thepraticolab.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/Domenico-Pratico\/pfbid02JhsGw29fbYaMRVRwXLeG2WMzVGJFNoLuQtpgewCCP9U1XHgHwWvYiQyLqXDJgjd8l\/","https:\/\/x.com\/DomenicPratico1","https:\/\/www.linkedin.com\/in\/domenico-pratico-a57817262\/?original_referer=httpswww.pratico-lab.com"]},{"@type":"Person","@id":"https:\/\/thepraticolab.com\/#\/schema\/person\/e82b3365d082813f155670a67aa9e909","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepraticolab.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ca8ef8f4c2ed934c1d85f121fd2b164b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8ef8f4c2ed934c1d85f121fd2b164b?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/thepraticolab.com"],"url":"https:\/\/thepraticolab.com\/post\/author\/pratico\/"}]}},"_links":{"self":[{"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/posts\/2867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/comments?post=2867"}],"version-history":[{"count":5,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/posts\/2867\/revisions"}],"predecessor-version":[{"id":2874,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/posts\/2867\/revisions\/2874"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/media\/2871"}],"wp:attachment":[{"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/media?parent=2867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/categories?post=2867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepraticolab.com\/wp-json\/wp\/v2\/tags?post=2867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"Alzheimer\u2019s](\"https:\/\/thepraticolab.com\/wp-content\/uploads\/2024\/07\/Alzheimers-disease-drug-development-an-update-1-800x450.png\")
\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\tAlzheimer\u2019s disease (AD) affects a significant portion of older individuals, with its prevalence expected to rise in the coming years. Therefore, urgent strategies for prevention and pharmacologic treatments are crucial. The state-of-the-art of drug development for AD plays a pivotal role in combating this disease, providing critical insights annually.\n![\"icons8-twitterx-50\"](\"https:\/\/thepraticolab.com\/wp-content\/uploads\/elementor\/thumbs\/icons8-twitterx-50-qmr90483uehgk5thzvyt7v4kehdf005w7nn3bslbcc.png\" "\\"icons8-twitterx-50\\"")
\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\n\t\t\t\n\t\t\t\t\t\t![\"icons8-facebook-60\"](\"https:\/\/thepraticolab.com\/wp-content\/uploads\/elementor\/thumbs\/icons8-facebook-60-qmr903a9nkg68juv5dk6ndd3t3i1sb25vizluimpik.png\" "\\"icons8-facebook-60\\"")
\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t![\"icons8-linkedin-logo-50\"](\"https:\/\/thepraticolab.com\/wp-content\/uploads\/elementor\/thumbs\/icons8-linkedin-logo-50-qmr901el9wdllbxlgcqxidu6mbrbcwup79omvyphv0.png\" "\\"icons8-linkedin-logo-50\\""){kind=logo}
\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t